Two years later, Novo Nordisk’s $3.3 billion buyout of Dicerna Pharmaceuticals’ RNAi platform is beginning to pay off. Novo scored an approval on Monday for nedosiran, an RNAi therapy developed by Dicerna to treat a rare kidney disease called primary hyperoxa…